Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9700-5
Annals of Surgical Oncology 15:745-753 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Leeuwen, B. L.
Right arrow Articles by Mahteme, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Leeuwen, B. L.
Right arrow Articles by Mahteme, H.

Original Article

Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis

B. L. van Leeuwen, MD, PhD, W. Graf, MD, PhD, L. Pahlman, MD, PhD and H. Mahteme, MD, PhD

Department of Surgical Sciences, Akademiska Sjukhuset, Uppsala University Hospital, SE 751 85, Uppsala, Sweden

Correspondence: Address correspondence and reprint requests to: H. Mahteme, MD, PhD; E-mail: Haile.Mahteme{at}kirurgi.uu.se

Background: Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. This prospective non-randomized study was designed to identify factors associated with postoperative morbidity and survival after peritonectomy HIPEC in patients with this condition.

Method: Data were prospectively collected from all patients with peritoneal carcinomatosis treated by means of peritonectomy and HIPEC at Uppsala University Hospital between October 2003 and September 2006. Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion.

Results: A total of 103 patients were treated. Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian cancer (6 patients) and mesothelioma (5 patients). Postoperative morbidity was 56.3% and was significantly lower in patients treated with mitomycin C for pseudomyxoma peritonei (42% ) than in those with another diagnosis treated with platinum compound (71% , P < 0.05). Postoperative mortality was less than 1% . At 2 years, overall survival was estimated to be 72.3% , and disease-free survival was 33.5% . Factors influencing overall and disease-free survival were tumor type and optimal cytoreduction.

Conclusion: Postoperative morbidity is dependent mainly on a tumor type; however, the chemotherapeutic agent used might also influence morbidity. Survival is determined by optimal cytoreduction and tumor type. Irrespective of age, patients with good performance status benefit from this treatment.

Key Words: Peritonectomy • HIPEC • Peritoneal carcinomatosis




This article has been cited by other articles:


Home page
 In VivoHome page
S. ASERO, M. CARUSO, N. VALLONE, A.G. LUCIANI, V. LOMBARDO, G. TERRANOVA, G. ETTORE, and G. GIANNONE
Cytoreductive Surgery (CS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treatment of Peritoneal Surface Malignances: Report of a Phase II Clinical Study
In Vivo, July 1, 2009; 23(4): 645 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
E. A. Levine, B. M. Ronnett, P. F. Mansfield, and C. Eng
Overview of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
ASCO Educational Book, January 1, 2008; 2008(1): 153 - 159.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.